Ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in experimental autoimmune encephalitis.
Bendszus
Martin
M
Stoll
Guido
G
D000818:Animals; D001812:Blood-Brain Barrier; D001921:Brain / Q000378:metabolism / Q000473:pathology*; D003287:Contrast Media; D003911:Dextrans; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000175:diagnosis* / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D052203:Ferrosoferric Oxide; D000068876:Fingolimod Hydrochloride; D006571:Heterocyclic Compounds; D007150:Immunohistochemistry; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007501:Iron; D008264:Macrophages / Q000473:pathology*; D008279:Magnetic Resonance Imaging; D058185:Magnetite Nanoparticles; D009942:Organometallic Compounds; D010087:Oxides; D011409:Propylene Glycols / Q000627:therapeutic use*; D051381:Rats; D043562:Receptors, G-Protein-Coupled / Q000819:agonists; D049312:Receptors, Lysophospholipid; D012008:Recurrence; D013110:Sphingosine
D003287:Contrast Media; D003911:Dextrans; D006571:Heterocyclic Compounds; D007166:Immunosuppressive Agents; D058185:Magnetite Nanoparticles; D009942:Organometallic Compounds; D010087:Oxides; D011409:Propylene Glycols; D043562:Receptors, G-Protein-Coupled; D049312:Receptors, Lysophospholipid; C097921:ferumoxtran-10; D007501:Iron; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine; D052203:Ferrosoferric Oxide